FFA
JAZZ icon

Fairfield Financial Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Fairfield Financial Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-60
Closed -$7.44K – 308
2023
Q2 		$7.44K Hold
60
– – ﹤0.01% 254
2023
Q1 		$8.7K Hold
60
– – ﹤0.01% 249
2022
Q4 		$9.56K Hold
60
– – ﹤0.01% 222
2022
Q3 		$8K Hold
60
– – ﹤0.01% 232
2022
Q2 		$9.36K Hold
60
– – ﹤0.01% 215
2022
Q1 		$9.34K Buy
+60
New +$8.71K ﹤0.01% 228

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Fairfield Financial Advisors's JAZZ Position: Q3 2023 in Review

Fairfield Financial Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2023, closing a stake of 60 shares — an estimated $7.44K sold.

Fairfield Financial Advisors first reported a position in JAZZ in Q1 2022 and held it in 6 quarters. The position peaked at $9.56K in Q4 2022. 484 funds tracked by Wall St. Rank hold JAZZ as of Q3 2023.

  • Fairfield Financial Advisors reported no remaining Jazz Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Fairfield Financial Advisors sold 60 Jazz Pharmaceuticals shares in Q3 2023, an estimated $7.44K.
  • Fairfield Financial Advisors first reported a position in Jazz Pharmaceuticals in Q1 2022 and held it in 6 quarters.
  • Fairfield Financial Advisors's Jazz Pharmaceuticals position peaked at $9.56K in Q4 2022.
  • 484 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2023.

Based on Fairfield Financial Advisors's 13F filing for Q3 2023, filed 4 Nov 2024.